Wealth Preservation Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Wealth Preservation Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6	Buy	+1	New	+$7	﹤0.01%	1019

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Preservation Advisors's RNAC Position: Q1 2026 in Review

Wealth Preservation Advisors opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #1019 among its holdings.

83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Wealth Preservation Advisors held 1 share of Cartesian Therapeutics worth $6 as of Q1 2026.
Cartesian Therapeutics was a new Wealth Preservation Advisors position in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of Wealth Preservation Advisors's portfolio in Q1 2026, its #1019 holding.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Wealth Preservation Advisors's 13F filing for Q1 2026, filed 15 May 2026.